These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

832 related articles for article (PubMed ID: 18277626)

  • 21. [Plasma level and prognostic significance of VEGF, bFGF and MMP-9 in patients with advanced non-small-cell lung cancer].
    Zhao J; Liu XY; Zhang QY; Jiang W
    Zhonghua Zhong Liu Za Zhi; 2005 Nov; 27(11):676-9. PubMed ID: 16438890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Angiogenic cytokines in serum and cutaneous lesions of patients with polyarteritis nodosa.
    Kikuchi K; Hoashi T; Kanazawa S; Tamaki K
    J Am Acad Dermatol; 2005 Jul; 53(1):57-61. PubMed ID: 15965421
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study.
    Martell RE; Peterson BL; Cohen HJ; Petros WP; Rai KR; Morrison VA; Elias L; Shepherd L; Hines J; Larson RA; Schiffer CA; Hurwitz HI
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):37-45. PubMed ID: 12111110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Expression of angiogenic factors and their clinical significances in acute myeloid leukemia].
    Wang Y; Xiao ZJ; Liu P; Peng Z; Han ZC
    Ai Zheng; 2004 Nov; 23(11 Suppl):1423-7. PubMed ID: 15566649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Long-term results with fludarabine monotherapy in chronic lymphocytic leukemia].
    Varga F; Lehoczky D; Demeter J
    Orv Hetil; 1999 Aug; 140(31):1731-5. PubMed ID: 10463032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma concentrations of vascular endothelial growth factor and basic fibroblast growth factor in lymphoproliferative disorders.
    Smolej L; Andrýs C; Maisnar V; Pour L; Malý J
    Acta Medica (Hradec Kralove); 2005; 48(1):57-8. PubMed ID: 16080387
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma levels of basic fibroblast growth factor and vascular endothelial growth factor and their association with IgVH mutation status in patients with B-cell chronic lymphocytic leukemia.
    Smolej L; Andrys C; Peková S; Schwarz J; Belada D; Zák P
    Haematologica; 2006 Oct; 91(10):1432-3. PubMed ID: 17018398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vascular endothelial growth factor and basic fibroblast growth factor in polycystic ovary syndrome during controlled ovarian hyperstimulation.
    Artini PG; Monti M; Matteucci C; Valentino V; Cristello F; Genazzani AR
    Gynecol Endocrinol; 2006 Aug; 22(8):465-70. PubMed ID: 17012110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
    Tsimberidou AM; Keating MJ; Giles FJ; Wierda WG; Ferrajoli A; Lerner S; Beran M; Andreeff M; Kantarjian HM; O'Brien S
    Cancer; 2004 Jun; 100(12):2583-91. PubMed ID: 15197800
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
    O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki A; Koziner B; Chanan-Khan AA; Seymour JF; Bociek RG; Pavletic S; Rai KR
    J Clin Oncol; 2007 Mar; 25(9):1114-20. PubMed ID: 17296974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modern prognostic factors and angiogenesis in chronic lymphocytic leukemia: more data needed.
    Smolej L; Andrys C; Vroblova V
    Leuk Res; 2007 Dec; 31(12):1763-4. PubMed ID: 17617454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic effects of surgery: quantitative analysis of circulating basic fibroblast growth factor (bFGF), Vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF-beta) in patients with breast cancer who underwent limited or extended surgery.
    Curigliano G; Petit JY; Bertolini F; Colleoni M; Peruzzotti G; de Braud F; Gandini S; Giraldo A; Martella S; Orlando L; Munzone E; Pietri E; Luini A; Goldhirsch A
    Breast Cancer Res Treat; 2005 Sep; 93(1):35-40. PubMed ID: 16184456
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and soluble interleukin-2 receptor (sIL-2R) concentrations in peripheral blood as markers of pituitary tumours.
    Komorowski J; Jankewicz J; Stepień H
    Cytobios; 2000; 101(398):151-9. PubMed ID: 10755214
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
    Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF
    Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
    McMeekin DS; Sill MW; Darcy KM; Stearns-Kurosawa DJ; Webster K; Waggoner S; Benbrook D
    Gynecol Oncol; 2007 Sep; 106(3):596-603. PubMed ID: 17597196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population.
    Perkins JG; Flynn JM; Howard RS; Byrd JC
    Cancer; 2002 Apr; 94(7):2033-9. PubMed ID: 11932906
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiogenesis and other markers for prediction of survival in metastatic renal cell carcinoma.
    Alamdari FI; Rasmuson T; Grankvist K; Ljungberg B
    Scand J Urol Nephrol; 2007; 41(1):5-9. PubMed ID: 17366095
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
    Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
    J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of circulating cytokeratin fragments and angiogenic factors in NSCLC patients stage IIIa-IIIb receiving curatively intended treatment.
    Eriksson P; Brattström D; Hesselius P; Larsson A; Bergström S; Ekman S; Goike H; Wagenius G; Brodin O; Bergqvist M
    Neoplasma; 2006; 53(4):285-90. PubMed ID: 16830054
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The peritoneal cavity is a distinct compartment of angiogenic molecular mediators.
    Nachtsheim R; Dudley B; McNeil PL; Howdieshell TR
    J Surg Res; 2006 Jul; 134(1):28-35. PubMed ID: 16650862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.